Osteonecrosis in human immunodeficiency virus-infected patients may not be related to immune reconstitution.

نویسنده

  • D J Skiest
چکیده

with ciprofloxacin at a dosage of 500–750 mg b.i.d. for 10–28 days. It should be noted, however, that, in the latter report, the interval between onset of disease and start of treatment with ciprofloxacin was not specified, and, in 4 of 7 cases with relapse, ciprofloxacin was used as a secondary therapy. We recently reported successful treatment of ulceroglandular tularemia with oral ciprofloxacin in 12 pediatric patients [3]. Here we report additional data from an outbreak of this disease in 1998 in central Sweden, where 43 patients (median age, 51 years; range, 21–83 years) were treated primarily with oral ciprofloxacin. Diagnosis was confirmed by use of serological tests and/or culture, and in 11 cases also by use of PCR, all performed according to methods described elsewhere [4]. For 41 of the 43 patients (24 with ulceroglandular, 3 with pulmonary, and 14 with typhoidal tularemia), the response to ciprofloxacin at a dosage of 500–750 mg b.i.d. for 10 days was excellent and no complications or relapse occurred. For these patients, the mean interval from onset of disease to initiation of ciprofloxacin therapy was 3.7 days (median, 3 days; range, 0–14 days). Two patients experienced complications. One patient, who presented 5 days after onset of typhoidal/pulmonary tularemia, responded well to a 10-day course of ciprofloxacin but relapsed 7 days after the end of treatment, with fever, arthralgia, and a pulmonary infiltrate. For another patient, treatment with ciprofloxacin was initiated 3 weeks after the onset of ulceroglandular tularemia; 20 days later, a lymph node abscess developed. With respect to new options for the treatment of tularemia, conclusions should be based mainly on results from primary use of a drug. For patients who have previously received a course of treatment with another drug, the evaluation is more difficult. Moreover, in cases where there is considerable delay before initiation of treatment, the development of lymph node abscesses or other complications may no longer be prevented by antibiotic agents that are appropriate for Francisella tularensis [5]. Previous reports on clinical use of quinolones [1, 3] and the present data, together with in vitro assays showing that quinolones have MIC values well below 0.1 mg/ml [3, 6, 7] and have in vivo efficacy with experimentally induced tularemia [8], argue strongly for the use of quinolones as alternative agents for the treatment of tularemia.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

The Prevalence of Different Human Immunodeficiency Virus Transmission Routes and Knowledge about AIDS in Infected People with HIV in Sirjan

Background & Objective: The immune system of Patients with Acquired Immune Deficiency Syndrome (AIDS) is weekend because of Human immunodeficiency virus (HIV) infection, and they become vulnerable to several opportunistic and non-opportunistic pathogens and different carcinomas. IV drug abuse, sexual contact, occupational transmission, blood transfusion and maternal-fetal transmission are well ...

متن کامل

Tetanus and Diphtheria Seroprevalence in Patients Infected With Human Immunodeficiency Virus

Background and Objectives: HIV infected patients are at risk for vaccine-preventable infections such as tetanus and diphtheria (Td). In these patients, these antibodies tend to decline faster. Due to the limited data, this study assessed the seroprevalence of tetanus and diphtheria antibodies in HIV infected patients in Tehran, Iran. Materials and Methods: This case-control study was carried o...

متن کامل

Mutations in the Basal Core Promoter and Precore/Core Regions of Hepatitis B Virus in Patients Co-Infected With Human Immunodeficiency Virus

ABSTRACT          Background and objectives: Globally, about one third of the population has been infected with Hepatitis B virus (HBV) and more than 400 million people have become chronically infected. Nearly, 20-25% of all carriers develop serious liver diseases such as cirrhosis, chronic hepatitis and hepatocellular carcinoma (HCC). According to t...

متن کامل

Human Immunodeficiency Virus (HIV) and Cardiomyopathy: A Systematic Review

Human immunodeficiency virus (HIV) infection has been associated with cardiac disease, including anatomical or functional disturbance to the heart. Cardiomyopathy (CMP) is one of these disturbances that have been associated with high rates of morbidity and mortality. In this review article, several aspects of potential relationships between HIV infection and cardiomyopathy development have been...

متن کامل

Cytomegalovirus Active Infection in Persons Infected with Human Immunodeficiency Virus

Background and Objective: Cytomegalovirus (CMV), one of the most common opportunistic pathogens in patients infected with human immunodeficiency virus (HIV), can cause the diseases such as encephalitis, pneumonia, and chorioretinitis. This study aimed at molecular studying of CMV infection in individuals infected with the human immunodeficiency virus. Material and Methods: In this study, 50 ven...

متن کامل

Quantification Analysis of Dot Blot Assays for Human Immunodeficiency Virus Type 1 and 2 Antibodies

Objective Dot Blot (DB) assay provides highly specific results, but usually not reliable for quantification of antibody production. The need for a more objective DB assay to provide a better definition of the immune status, against HIV antigens, promoted this study to be done to develop a quantitative DB assay. Material and Methods Dot blot (DB) strips for antibodies directed to human immuno...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

دوره 33 2  شماره 

صفحات  -

تاریخ انتشار 2001